title: Report from the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9-10, 2001.
authors.forename: T
authors.initials: T
authors.lastname: Fleming
authors.forename: J
authors.initials: J
authors.lastname: Lindenfeld
authors.forename: R
authors.initials: R
authors.lastname: Lipicky
authors.forename: P
authors.initials: P
authors.lastname: Armstrong
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D000077300:Bosentan; D000075202:Contraindications; D017277:Drug Approval; D004347:Drug Interactions; D016903:Drug Monitoring; D023381:Endpoint Determination; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D013449:Sulfonamides; D014665:Vasodilator Agents; D011464:Epoprostenol; D000077300:Bosentan; C427248:treprostinil